The notices it replaced
Its page names no earlier notice: it is new, or it does not say.
Replaced by PAR-18-762.
Who won it before
11 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $3,978,360 in first-year total cost, median $390,626.
Most frequent study sections
- Neurological Sciences and Disorders B Study Section[NSD-B]7
- Neurological Sciences and Disorders A Study Section[NSD-A]3
- Neurological Sciences and Disorders C Study Section[NSD-C]1
Most frequent institutions
- CHAPMAN UNIVERSITY1
- DUKE UNIVERSITY1
- JOHNS HOPKINS UNIVERSITY1
- MASSACHUSETTS GENERAL HOSPITAL1
- RBHS-ROBERT WOOD JOHNSON MEDICAL SCHOOL1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2019 | GALV-Based Retroviral Replicating Vectors for Glioma Gene Therapy1R21NS104454-01A1 | KASAHARA, NORIYUKI | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $401,456 | NSD |
| 2019 | Slack Potassium Channel Inhibitors for the Treatment of Childhood Epilepsies1R21NS109521-01 | EMMITTE, KYLE AWEAVER, C DAVID | VANDERBILT UNIVERSITY, TN | $290,733 | NSD |
| 2018 | Immortalized Striatal Precursor Neurons as a Screenable Model of HD1R21NS104320-01A1 | ROSS, CHRISTOPHER A | JOHNS HOPKINS UNIVERSITY, MD | $403,537 | NSD |
| 2018 | High-content screening for modulators of lamin B1 as a therapeutic target in autosomal dominant leukodystrophy1R21NS106087-01 | PADIATH, QUASAR SVOGT, ANDREAS | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $390,626 | NSD |
| 2018 | Small molecule stabilizers of Hsp70 for treatment of spinal and bulbar muscular atrophy1R21NS101030-01A1 | LIEBERMAN, ANDREW POSAWA, YOICHI | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $388,542 | NSD |
| 2018 | Development of SK channel modulators as therapeutic agents for ataxia1R21NS101182-01A1 | BEZPROZVANNY, ILYA BZHANG, MIAO | CHAPMAN UNIVERSITY, CA | $186,750 | NSD |
| 2017 | Developing Novel RNA-Based Therapeutics for Parkinson's Disease1R21NS096032-01A1 | DISNEY, MATTHEW DMOURADIAN, M. MARAL | RBHS-ROBERT WOOD JOHNSON MEDICAL SCHOOL, NJ | $452,438 | NSD |
| 2017 | Anticonvulsant screening using chronic epilepsy models1R21NS096948-01A1 | BERDICHEVSKY, YEVGENYDUDEK, F. EDWARDDULLA, CHRIS GSTALEY, KEVIN J. | MASSACHUSETTS GENERAL HOSPITAL, MA | $443,878 | NSD |
| 2017 | Discovery of Post-transcriptional utrophin upregulator small molecules for Duchenne Muscular Dystrophy therapeutics1R21NS102838-01 | KHURANA, TEJVIR S | UNIVERSITY OF PENNSYLVANIA, PA | $402,500 | NSD |
| 2017 | Allele-specific RNA-targeted lead compounds for Huntington's disease1R21NS099516-01A1 | WARNER, KATHERINE DEIGAN | RIBOMETRIX, LLC, NC | $260,150 | NSD |
| 2016 | Inhibitors of TrkB Signaling1R21NS094863-01 | MCNAMARA, JAMES O. | DUKE UNIVERSITY, NC | $357,750 | NSD |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.